Clinical trials
Phase 4 Carcinoma, Hepatocellular trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 3 |
| 2007 | 6 |
| 2010 | 3 |
| 2011 | 5 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 25 |
| Completed | 8 |
| Terminated | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 15 |
| Fudan University | 2 |
| Qidong Gaitianli Medicines Co., Ltd | 2 |
| The Second Affiliated Hospital of Chongqing Medical University | 2 |
| Anhui Provincial Hospital | 1 |
| Beijing Ditan Hospital | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 36 |
| Liver Neoplasms | 7 |
| Hepatitis B | 3 |
| Pain | 3 |
| Recurrence | 3 |
| Hepatitis B, Chronic | 2 |
| Liver Diseases | 2 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Fibrosis | 1 |
| Inflammation | 1 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.